Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial von Hughes, B.G.M., Munoz-Couselo, E., Mortier, L., Bratland, Å., Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R.F., Grob, J.-J.

Volltext

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma von Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

Volltext

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma von Long, Georgina V, Stroyakovskiy, Daniil, Gogas, Helen, Levchenko, Evgeny, de Braud, Filippo, Larkin, James, Garbe, Claus, Jouary, Thomas, Hauschild, Axel, Grob, Jean Jacques, Chiarion Sileni, Vanna, Lebbe, Celeste, Mandalà, Mario, Millward, Michael, Arance, Ana, Bondarenko, Igor, Haanen, John B.A.G, Hansson, Johan, Utikal, Jochen, Ferraresi, Virginia, Kovalenko, Nadezhda, Mohr, Peter, Probachai, Volodymyr, Schadendorf, Dirk, Nathan, Paul, Robert, Caroline, Ribas, Antoni, DeMarini, Douglas J, Irani, Jhangir G, Casey, Michelle, Ouellet, Daniele, Martin, Anne-Marie, Le, Ngocdiep, Patel, Kiran, Flaherty, Keith

Volltext

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study von Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Volltext

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study von McArthur, G.A., Maio, M., Arance, A., Nathan, P., Blank, C., Avril, M.-F., Garbe, C., Hauschild, A., Schadendorf, D., Hamid, O., Fluck, M., Thebeau, M., Schachter, J., Kefford, R., Chamberlain, M., Makrutzki, M., Robson, S., Gonzalez, R., Margolin, K.

Volltext

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee von Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Michielin, O.

Volltext

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial von Guo, J., Carvajal, R.D., Dummer, R., Hauschild, A., Daud, A., Bastian, B.C., Markovic, S.N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T.M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F.S.

Volltext

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee von Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Keilholz, U.

Volltext

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma von Owen, C.N., Bai, X., Quah, T., Lo, S.N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I.L.M., Thompson, N., Vanella, V., Gerard, C.L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C.U., Welsh, S.J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J.L., Ascierto, P.A., Zimmer, L., Johnson, D.B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M.S., Sullivan, R.J., Long, G.V., Menzies, A.M.

Volltext

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types von Paré, L., Pascual, T., Seguí, E., Teixidó, C., Gonzalez-Cao, M., Galván, P., Rodríguez, A., González, B., Cuatrecasas, M., Pineda, E., Torné, A., Crespo, G., Martin-Algarra, S., Pérez-Ruiz, E., Reig, Ò, Viladot, M., Font, C., Adamo, B., Vidal, M., Gaba, L., Muñoz, M., Victoria, I., Ruiz, G., Viñolas, N., Mellado, B., Maurel, J., Garcia-Corbacho, J., Molina-Vila, M Á, Juan, M., Llovet, J.M., Reguart, N., Arance, A., Prat, A.

Volltext

Vasculitic neuropathy induced by pembrolizumab von Aya, F., Ruiz-Esquide, V., Viladot, M., Font, C., Prieto-González, S., Prat, A., Arance, A.

Volltext

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study von Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., Rooney, I., Voulgari, A., Troutman, S., Pitcher, B., Guo, Y., Yan, Y., Castro, M., Mulla, S., Flaherty, K., Arance, A.

Volltext

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up von Amaral, T., Ottaviano, M., Arance, A., Blank, C., Chiarion-Sileni, V., Donia, M., Dummer, R., Garbe, C., Gershenwald, J.E., Gogas, H., Guckenberger, M., Haanen, J., Hamid, O., Hauschild, A., Höller, C., Lebbé, C., Lee, R.J., Long, G.V., Lorigan, P., Muñoz Couselo, E., Nathan, P., Robert, C., Romano, E., Schadendorf, D., Sondak, V., Suijkerbuijk, K.P.M., van Akkooi, A.C.J., Michelin, O., Ascierto, P.A.

Volltext

Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase... von Hughes, B.G.M., Munoz-Couselo, E., Mortier, L., Bratland, Å., Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R.F., Grob, J.-J.

Volltext

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006 von Long, G.V., Arance, A., Mortier, L., Lorigan, P., Blank, C., Mohr, P., Schachter, J., Grob, J.-J., Lotem, M., Middleton, M.R., Neyns, B., Steven, N., Ribas, A., Walpole, E., Carlino, M.S., Lebbe, C., Sznol, M., Jensen, E., Leiby, M.A., Ibrahim, N., Robert, C.

Volltext

Real‐world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab von Mohr, P., Ascierto, P., Arance, A., McArthur, G., Hernaez, A., Kaskel, P., Shinde, R., Stevinson, K.

Volltext

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study von Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Volltext

Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts von Gaudy-Marqueste, C, Grob, J J, Garbe, C, Ascierto, P A, Arron, S, Basset-Seguin, N, Bohne, A S, Lenoir, C, Dummer, R, Fargnoli, M C, Guminski, A, Hauschild, A, Kaufmann, R, Lallas, A, Del Marmol, V, Migden, M, Penicaud, M, Rembielak, A, Stratigos, A, Tagliaferri, L, Zalaudek, I, Arance, A, Badinand, D, Bossi, P, Challapalli, A, Clementi, M, Di Stefani, A, Ferrándiz-Pulido, C, Giuffrida, R, Gravina, G L, Ha, P, Heinzerling, L, Mallet, S, Paradisi, A, Mohr, P, Piccerillo, A, Rutkowski, D, Saiag, P, Sollena, P, Trakatelli, M, Wojcieszek, P, Yom, S S, Zelin, E, Peris, K, Malvehy, J

Volltext

SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) von Majem, M., García-Martínez, E., Martinez, M., Muñoz-Couselo, E., Rodriguez-Abreu, D., Alvarez, R., Arance, A., Berrocal, A., de la Cruz-Merino, L., Lopez-Martin, J. A.

Volltext

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma von Tawbi, Hussein A, Schadendorf, Dirk, Lipson, Evan J, Ascierto, Paolo A, Matamala, Luis, Castillo Gutiérrez, Erika, Rutkowski, Piotr, Gogas, Helen J, Lao, Christopher D, De Menezes, Juliana Janoski, Dalle, Stéphane, Arance, Ana, Grob, Jean-Jacques, Srivastava, Shivani, Abaskharoun, Mena, Hamilton, Melissa, Keidel, Sarah, Simonsen, Katy L, Sobiesk, Anne Marie, Li, Bin, Hodi, F. Stephen, Long, Georgina V

Volltext